1. Home
  2. HPP vs EVMN Comparison

HPP vs EVMN Comparison

Compare HPP & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hudson Pacific Properties Inc.

HPP

Hudson Pacific Properties Inc.

HOLD

Current Price

$6.06

Market Cap

553.0M

Sector

Finance

ML Signal

HOLD

EVMN

Evommune Inc.

N/A

Current Price

$23.60

Market Cap

892.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HPP
EVMN
Founded
1997
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
553.0M
892.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HPP
EVMN
Price
$6.06
$23.60
Analyst Decision
Hold
Strong Buy
Analyst Count
11
9
Target Price
$15.45
$43.29
AVG Volume (30 Days)
1.2M
299.2K
Earning Date
05-06-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.67
$13.89
52 Week High
$14.95
$33.20

Technical Indicators

Market Signals
Indicator
HPP
EVMN
Relative Strength Index (RSI) 37.18 46.88
Support Level $5.55 $21.86
Resistance Level $7.99 $33.20
Average True Range (ATR) 0.47 2.07
MACD -0.02 -0.39
Stochastic Oscillator 12.07 35.11

Price Performance

Historical Comparison
HPP
EVMN

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: